Ironwood Pharmaceuticals ex-officer proposes $377K sale

The remarks say the planned sales relate to taxes from vesting of stock awards.

Available on EDGAR 09/23/2026 - 04:09 PM EDT Accepted by SEC EDGAR 09/23/2026 - 04:08 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Ironwood Pharmaceuticals Inc. (IRWD) lists a proposed sale by former officer Michael Shetzline of 83,306 Class A common shares through E Trade Securities LLC, with an approximate sale date of September 24, 2026, on Nasdaq. The stated aggregate market value is $377,376.18. Shetzline stated that the shares are to be sold to cover taxes from vesting of stock awards.

Key Figures

Proposed sale: 83,306 Class A common shares Aggregate market value: $377,376.18 Class A common shares outstanding: 165,239,947 shares

3 metrics

Proposed sale 83,306 Class A common shares Michael Shetzline; approximate sale date September 24, 2026

Aggregate market value $377,376.18 Class A common shares listed for sale

Class A common shares outstanding 165,239,947 shares Issuer share count stated with the sale information

Key Terms

Rule 144, Restricted Stock Unit award, 2019 Equity Incentive Plan

3 terms

Rule 144 regulatory

"definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Unit award financial

"Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan"

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

2019 Equity Incentive Plan financial

"Issuer's 2019 Equity Incentive Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IRWD shares did Michael Shetzline propose to sell?

The notice lists 83,306 Class A common shares for sale, with an approximate sale date of September 24, 2026, through E Trade Securities LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001808509
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	IRONWOOD PHARMACEUTICALS INC
SEC File Number	001-34620
Address of Issuer	100 SUMMER STREET, SUITE 2300 BOSTON MASSACHUSETTS 02110
Phone	617-621-7722
Name of Person for Whose Account the Securities are To Be Sold	Shetzline Michael
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common Stock	E Trade Securities LLC 3 Edison Drive Alpharetta GA 30005	83306	377376.18	165239947	09/24/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common Stock	03/08/2023	Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan	Ironwood Pharmaceuticals, Inc.			17467	03/08/2023	N/A
Class A Common Stock	02/12/2024	Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan	Ironwood Pharmaceuticals, Inc.			13606	02/12/2024	N/A
Class A Common Stock	02/12/2024	Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan	Ironwood Pharmaceuticals, Inc.			12447	02/12/2024	N/A
Class A Common Stock	02/10/2025	Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan	Ironwood Pharmaceuticals, Inc.			33333	02/10/2025	N/A
Class A Common Stock	02/10/2025	Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan	Ironwood Pharmaceuticals, Inc.			30494	02/10/2025	N/A
Class A Common Stock	03/10/2026	Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan	Ironwood Pharmaceuticals, Inc.			34153	03/10/2026	N/A
Class A Common Stock	03/10/2026	Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan	Ironwood Pharmaceuticals, Inc.			31244	03/10/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	Shares sold to cover taxes from the vesting of stock awards granted by the Issuer.
Date of Notice	09/23/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Michael Shetzline
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)